Kezar Life Sciences

As the year draws to a close, we want to take a moment to extend our warmest wishes to you and your loved ones. We hope this time brings you peace and joy.

This , Kezar wishes to express heartfelt gratitude. To patients who inspire us daily with their courage, to patient advocacy groups championing the cause, to our collaborating physicians for their dedication, and to our unwavering team: Thank you. Your trust, collaboration, and resilience drive us to advance novel therapies for immune-mediated and oncologic disorders. We are thankful for each one of you as we journey together toward a brighter, healthier future.

Discover more about PORTOLA, a study evaluating , an investigational drug as a potential new treatment for AIH, and access further study details here: kezarlifesciences.com/patients/clinical-trials

Our Phase 2b trial is actively enrolling people living with ( ). Learn about our patient-centric approach and more on the trial here: https://palizadetrial.com/

Join us TODAY (Tuesday, Sept. 26) from 12-1 p.m. ET for an educational webinar sponsored by Kezar Life Sciences, “The Truth About Clinical Trials: Debunking Four Common Myths."

Use this link to join the webinar: https://iu.zoom.us/j/85265740704

Dr. Ethan Weinberg, a site Principal Investigator for the PORTOLA Clinical Trial, will lead a talk aiming to:

• Shed light on common myths about clinical trials
• Highlight the facts around clinical trial participation
• Explain how Kezar’s investigational product, zetomipzomib (KZR-616) may be able to help people living with AIH in the PORTOLA clinical trial.

More information about the PORTOLA trial can be found
here: https://clinicaltrials.gov/ct2/show/NCT05569759

The PORTOLA clinical trial (NCT05569759) aims to enroll patients who have not fully responded to standard treatments or who are experiencing flares of liver inflammation on standard treatments. Standard treatments for AIH have not advanced in more than 50 years, and the AIHA is excited that Kezar recognizes the need for new therapies for patients.

The webinar is sponsored by Kezar Life Sciences and the AIHA.

We’re proud to announce our strategic partnership with Everest Medicines to develop for the treatment of lupus nephritis and other potential indications in Greater China, South Korea , and Southeast Asia.

Read more about our new partnership here: https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-and-everest-medicines-enter-agreement

Don’t miss our CMO, Noreen R. Henig’s, M.D, panel discussion on patient-centric clinical trials at the HealthLeaders Pharma NOW Summit today. Register for today’s event here: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&eventid=2316043&sessionid=1&key=C43345E26DB1E1C464082F44BC6FC8A2&groupId=1695635&partnerref=hlsite&sourcepage=register

This week, our CMO, Noreen R. Henig, M.D., will participate in a panel, “Patients First – Including Patients in the Design of Clinical Trials,” at the virtual HealthLeaders Pharma NOW Summit. Register for the event here: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&eventid=2316043&sessionid=1&key=C43345E26DB1E1C464082F44BC6FC8A2&groupId=1695635&partnerref=hlsite&sourcepage=register

This week, our CMO, Noreen R. Henig, M.D., will participate in a panel, “Patients First – Including Patients in the Design of Clinical Trials,” at the virtual HealthLeaders Pharma NOW Summit. Register for the event here: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&eventid=2316043&sessionid=1&key=C43345E26DB1E1C464082F44BC6FC8A2&groupId=1695635&partnerref=hlsite&sourcepage=register

There are limited effective treatment options for patients with . Join us in our mission to improve the lives of those living with lupus nephritis and learn about our Trial here: https://kezarlifesciences.com/patients/clinical-trials

With over 30 years of experience in the development of drug products, our VP of Pharmaceutical Development, Rafael Sarabia, Ph.D., has led teams through the successful commercialization of multiple products. Learn about why he joined Kezar and more on his role: https://kezarlifesciences.com/about/team

As Chief Medical Officer, Noreen Roth Henig, M.D.’s breadth of experience across clinical practice and academia, and deep expertise in guides our work to develop first-in-class small molecule therapies for those living with diseases and . Learn about why she believes in our mission and more on her role as CMO here: https://kezarlifesciences.com/about/team

KZR-261 is the first candidate developed using our Protein Secretion Inhibition platform and is being investigated for the treatment of advanced . Learn about the collaborative work done on novel Sec61 inhibitors between our Kezar team, Jack Taunton and the Taunton Lab at UCSF and Ville Paavilainen and the Paavilainen group at the University of Helsinki in this Nature Reviews Drug Discovery article: https://www.nature.com/articles/d41573-023-00086-w

in the United States offers a time to reflect on and celebrate our nation’s independence, as well as our commitment to the ideals of hope and promise. From all of us at Kezar, happy Independence Day!

celebrates freedom and the emancipation of enslaved African Americans in the United States and serves as a reminder to commit to equity and education. Today and every day, we stand with and celebrate the contributions of the community and work to uplift diverse voices.

We’re celebrating our 8th anniversary! Innovation and belief has grown into a mission to deliver novel, first-in-class therapies for patients with a range of -mediated and disorders. We’re grateful for our team of individuals dedicated to our vision and look forward to what’s to come.

This , we stand with the + community and recognize the disparities that disproportionately impact patients who identify as LGBTQ+. Our Senior Director, Human Resources, Joe Tedrick, shares what the month means to him.

Do you have or know someone who has ? Our Trial is actively enrolling patients with lupus nephritis ( ). Learn more about the PALIZADE Study and access additional trial information here: https://kezarlifesciences.com/patients/clinical-trials.

May is . We’re proud to be developing novel therapies including to address an unmet need for those living with ( ). Learn more about lupus nephritis here: https://kezarlifesciences.com/patients/education